Skip to main content

Table 2 Univariate and multivariate analyses of the factors associated with IFN-γ production in response to the PPD antigen

From: Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients

Factor Univariable   Multivariablea  
  (IC95%) P-value (IC95%) P-value
Baseline CD4
 ≥ 200 cells/mm3 1   1  
 < 200 cells/mm3 1.375 (0.332;5.694) 0.661 5.547 (1.348;22.821) 0.018
Gender
 Male 1    
 Female 0.242 (0.052; 1.118) 0.069   
Age (Year)
 38–44 1   1  
 32–18 3.87 (1.336;11.212) 0.013 2.808 (1.13;6.98) 0.026
 37–32 1.256 (0.305;5.169) 0.752 1.061 (0.292; 3.862) 0.928
Site of tuberculosis
 Pulmonary 1   1  
 Disseminated 1.173 (0.285; 4.836) 0.825 1.531 (0.468; 5.01) 0.482
 Extrapulmonary 4.275 (1.122; 16.285) 0.033 6.431 (1.566; 26.408) 0.010
Ethnicity
 White 1    
 Black 2.544 (0.603; 10.737) 0.204   
 Mulattoes 1.376 (0.283; 6.705) 0.692   
Efavirenz dose
 600 mg 1   1  
 800 mg 3.187 (0.901;11.266) 0.072 3.505 (1.04;11.817) 0.043
HIV-1 viral load
 Detectable 1    
 Undetectable 2.348 (1.228;4.489) 0.010   
 Follow-up CD4 cells/mm3     
 ≥200 cells/mm3 1.003 (1.001; 1.005) 0.002 1.006 (1.003; 1.009) <0.001
 <200 cells/mm3 1.004 (0.996; 1.1014) 0.312 1.011 (1.002; 1.02) 0.016
Follow-up %HLA-DR+/CD3+ T cells 0.994 (0.975; 1.014) 0.559   
Follow-up % CD8+/38+ T cells 0.998 (0.972; 1.024) 0.851   
Follow-up IFN-γ plasmatic 0.989 (0.946; 1.033) 0.61   
  1. aThe predictors in the PPD antigen final model are as follows: Baseline CD4, Age, Site of tuberculosis, Efavirenz dose, Follow-up CD4 ≥ 200 cells/mm3 and Follow-up CD4 < 200 cells/mm3